Survey says new CMS rule may force hospital cardiac implant cutbacks; J&J hip implant lawsuit settled out of court;

 @FierceMedDev: Looks like the U.S. endoscopy device market will double over the next six years. Release | Follow @FierceMedDev

 @MarkHFierce: A CMS coverage decision could reduce the amount of cardiac implants hospitals perform each year, says a new survey. More | Follow @MarkHFierce

 @DamianFierce: Developers look for FDA approval for medical device-like apps. Article | Follow @DamianFierce

> Nearly 75% of hospital CFOs polled in a recent survey said their facilities would likely cut back the number of pacemaker, defibrillator and other electronic cardiac device implants in the face of a new Centers for Medicare and Medicaid Services rule affecting reimbursement, assuming they can offer alternative treatment options. Release

> The first lawsuit over Johnson & Johnson ($JNJ) unit DuPuy's ASR hip implant has been settled out of court, but the devicemaker still faces a bevy of similar suits around the world. Article

> Forbes takes a closer look at the controversy surrounding the FDA's surveillance of its own employees, reporting that the targeted scientists may have had a financial interest in leaking agency documents. Story

> InSightec got the FDA's blessing to start a Phase I trial evaluating the use of its ExAblate Neuro device in treating Parkinson's disease. Item

> Smiths Medical signed a deal with Nexus Medical to distribute the company's Nexus TKO anti-reflux needle free valves and extension sets. News

> LabCorp ($LH) wants to sell senior notes that will help fund general operations but also repay existing debt dating back to Dec. 21, 2011. Release

> Rosetta Genomics is predicting big growth in its microRNA diagnostic assays, and, to prepare, the company has expanded its executive leadership and lab capacity. Release

Biotech News

 @FierceBiotech: Check out FierceBiotechIT.com's 10 Big Pharma smartphone apps slideshow. Special Feature | Follow @FierceBiotech

 @JohnCFierce: J&J forking over another $50M milestone to Pharmacyclics for their btk partnership. Now that's how you reap biobucks. Release | Follow @JohnCFierce

 @RyanMFierce: DNA data-crunching contest draws Sanofi, NIH, others. Report | Follow @RyanMFierce

> Booming Pharmacyclics snags $50M paycheck as J&J pact drives blood cancer trials. More

> FDA calendar crowded with blockbuster decisions for Ironwood, Pfizer and Sanofi. News

> New lab organs promise faster, cheaper, better drug development. Report

> Regulus Therapeutics files for $58M IPO. Story

Pharma News

 @FiercePharma: China significantly ratchets back drugs on 'essential drugs' list. More | Follow @FiercePharma

> FDA has four big drug decisions lined up. Item

> Predictions for emerging markets hit new realities. Story

> Company convicted in gray market distribution scheme. Article

CRO News

> Report: 211 died in Indian trials in first half of 2012. More

> Icon banks on translational medicine with U.K. expansion. Item

> CROs: Go green to woo Pfizer. More

> INC picks three of its own for new C-level spots. Report

> Report: Indian CRO market will double, reach $1B in 2016. Story

Biotech IT News

> DNA data-crunching contest draws Sanofi, NIH, others. Story

> Lilly's 'big data' ally finds new Indy digs for IT workers. More

> Big data analytics bolsters hunt for elusive Huntington's drugs. Article

> Quintiles gains genomic, bioinformatics know-how in buyout. Item

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.